Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
FAIL · Does not pass the screen
26.18 USD
At the last full screen 2026-08-27
Screened 2026-08-27 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Aktis Oncology, Inc. holds its Accumulation at $26.18. Consolidating, no directional conviction, held for 9 days.
As held on the ledger · 2026-08-27
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 9 days
Price at the screen
$26.18
Valuation
N/A trailing · -12.61 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
4.36%
Below 33%
Interest-bearing debt is just 4.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
71.35%
Below 33%
Interest-bearing cash and securities are 71.4% of assets, above the one-third limit.
Fail
Receivables
14.26%
Below 49%
Money owed to the company is 14.3% of assets, under the 49% limit.
Pass
Revenue purity
169.45%
Below 5%
169.4% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. A 31.8% margin of safety to the base estimate.
Third-party analyst targets: 8 covering, consensus Strong Buy. The average target sits +32% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Early Radiopharma Bet Faces Binary Trial Hurdles
Aktis is trying to turn tiny proteins into guided missiles that deliver radiation straight to solid tumours. Revenue is exploding from a tiny base at 123 percent, yet the business still posts zero profit margins and a forward multiple of negative 12.7 times. Analysts see upside to 34 dollars from the current 24.89, but the opportunity rating sits at none because the company remains years from reliable cash flow.
The ethical screen clears, which keeps the name in scope, yet the lack of any proven moat leaves the whole story resting on one lead candidate that has yet to clear late-stage data. Clinical-stage radiopharma bets often burn cash faster than they can raise it, and any delay or safety signal can wipe out years of work overnight.
That combination of high growth, negative earnings and untested durability is exactly why we pass despite the headline discount to fair value. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AKTS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-21Accumulation$24.00-3.6%Entry 6
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $32.
2026-07-21Accumulation$24.89+13.5%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 13.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $32.
2026-07-18Accumulation$21.93+0.0%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $32.
2026-07-17Accumulation$21.93+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (5 analysts) rates it strong buy, with a mean price target of $32.
2026-07-03Accumulation$21.93+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Accumulation$21.93Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
